The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Biomarin Pharmaceuticals

  • BMRN
  • NASDAQ
  • Consumer Products
  • Latest 71.22
  • Currency US$
  • Change 1.60
  • Percent Change 2.298 %
  • Volume 678,442
  • Fri Aug 29, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 69.75
  • Previous Close 69.62
  • High 71.73
  • Low 69.68
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High02/27 84.25
  • 52-week Low04/15 55.04
  • Beta 0.771
  • Market Cap 10,324.05M
  • EPS -1.32
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $572,100,000
  • Earnings $-174,660,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $639,770,000
  • Current Ratio 7.99

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,340,720,000
  • Liabilities $880,600,000
  • Liabilities-to-Equity Ratio 0.60

Price Ratios

  • Price to Sales 18.05
  • Price to Book 7.07
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 30 $-0.42 Oct 23 $-0.19
Surprises Jul 30 -54.76% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Aug 30, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Related Securities
Symbol Type Latest % Chg

Officers

  • Pierre LaPalme Chairman and Director
  • Jean-Jacques Bienaime Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

770 Lindaro Street
San Rafael, CA
94949

Phone: (415)-506-6700
Fax: (415)-3827889

ir@bmrn.com
www.bmrn.com

Ideas & Discussion

Live Discussion of BMRN on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.